TenX Keane Acquisition
Status: Closed Deal
U=S+R
R=S/5
| IPO Proceeds, $M | $66.00M |
|---|---|
| IPO Date | Oct 14, 2022 |
| CEO | Xiaofeng Yuan |
| Left Lead | Maxim |
| IPO Cash in Trust | 102.0% |
| SPAC Tenor | 9 + 3 + 3 + 10 |
| IPO Sector | General ▶ |
| IPO Geography | Asia |
| Target Company | Citius Oncology, Inc. |
| Deal Announced | Oct 24, 2023 |
| Deal Size, $M | TBD |
| Deal Sector | Healthcare |
| Deal Geography | US/Canada |
| SEC Filings |
www.sec.gov 
|
| Approval Vote | Aug 2, 2024 |
| Amendment Vote | Jan 17, 2024 |
| Closing Date | Aug 12, 2024 |
Formerly TENK
CTOR
| Price | $1.67 |
|---|---|
| Last closing price | $1.72 |
| H/L, today | $1.68 / $1.75 |
| Volume, today | 396,328 |
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in to view structure, cap table, and calendar of events.